The Enigma of FGF23 Dysregulation in Von Recklinghausen’s Disease: A Case of Hypophosphatemic Osteomalacia with a Neurofibromin 1 Gene (c.6772C>T; p.Arg2258Ter) Mutation

Read full text Summarise with VIRAT
Authors: Naga Bhagyasri Mangam, Sandeep Reddy Devireddy, Prasun Deb, Smitha Nalla, Alekya Vulpala, Krishna Veni Nutakki, Thushara Nayani
Cited by: 0
References: 12

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Neurofibromatosis type 1 (NF-1) or Von Recklinghausen’s disease is an autosomal dominant disorder characterised by a variety of systemic manifestations including skeletal abnormalities. Hypophosphatemic Osteomalacia (HO) is a rare but significant complication associated with NF-1 primarily driven by Fibroblast Growth Factor 23 (FGF23)-mediated phosphate wasting. Case Presentation: We report the case of a 54-year-old male with NF-1 presenting with progressive proximal muscle weakness and osteomalacia. Diagnostic workup revealed insufficiency fractures, severe hypophosphatemia and increased FGF23 levels, suggestive of FGF23-mediated HO. Additional findings included a peri-ampullary neuroendocrine tumor and a Gastrointestinal Stromal Tumor (GIST). Genetic testing identified a heterozygous pathogenic variant (c.6772C>T; p.Arg2258Ter) in the NF-1 gene. The patient was managed with phosphate and calcitriol supplementation, leading to clinical and radiological improvement. Conclusion: Very few patients of Neurofibromatosis type 1 expressing HO is mysterious. NF-1-associated HO requires heightened clinical awareness for early diagnosis and intervention to alleviate the morbidity.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Neurofibromatosis and Schwannoma Cases Alkaline Phosphatase Research Studies

Publication details

Journal / source
Archives of Endocrinology and Disorders
Volume
2
Issue
1
Pages
1–11
Publication date
28 March 2026
Language
EN